Citizens Maintains Market Outperform on OptimizeRx, Raises Price Target to $11
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Citizens analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price target from $9 to $11.
Citizens analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price target from $9 to $11.